Literature DB >> 7848421

Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample.

R A Hiatt1, J D Ordoñez.   

Abstract

Screening urine for microhematuria as an indicator of serious disease is controversial because of the low positive predictive value of such screening and the costs and risks of the associated evaluation. To further evaluate test properties, we retrospectively examined the outcomes of 20,571 men aged > or = 35 years and women aged > or = 55 years who voluntarily had a Personal Health Appraisal in 1980 as members of a large prepaid health plan. Hematuria was detected by dipstick in 876 cases (4.3%); 278 were excluded because of evidence of previous urological disease which could cause hematuria. Review of the medical records of 598 patients with asymptomatic microhematuria as shown by a positive dipstick result indicated that 99% had a follow-up evaluation within 3 months of positive test results for hematuria and had various levels of urological evaluation thereafter. However, urological cancers (2 prostate, 1 bladder) developed in only 3 patients within the next 3 years. On the basis of San Francisco-Oakland Surveillance, Epidemiology, and End Results program data, rates of urological cancer were evaluated among patients whose test results were negative for hematuria, and these cancer rates were found to be almost the same as the rate among patients with asymptomatic microhematuria. Sensitivity of a single dipstick urinalysis result using microhematuria to indicate urological cancer within 3 years was 2.9%; specificity was 96.7%; and positive predictive value was 0.5%. Multivariate analysis which adjusted for age, gender, and race showed that the relative risk of 2.1 (95% confidence interval, 0.7-6.6) for urological cancer was not significantly elevated among patients with asymptomatic microhematuria compared with patients who had negative test results. These findings based on a single test are consistent with the current lack of recommendations for screening for microhematuria among asymptomatic adults.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7848421

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  18 in total

1.  Asymptomatic haematuria. All patients with haematuria should undergo cystoscopy.

Authors:  J Reynard
Journal:  BMJ       Date:  2000-06-10

Review 2.  Evidence based case report. Asymptomatic haematuria ... in the doctor.

Authors:  C Del Mar
Journal:  BMJ       Date:  2000-01-15

Review 3.  Time to abandon testing for microscopic haematuria in adults?

Authors:  Per-Uno Malmström
Journal:  BMJ       Date:  2003-04-12

Review 4.  Best practice in primary care pathology: review 2.

Authors:  W S Smellie; J O Forth; C A M McNulty; L Hirschowitz; D Lilic; R Gosling; D Bareford; E Logan; K G Kerr; G P Spickett; J Hoffman; A Galloway; C A Bloxham
Journal:  J Clin Pathol       Date:  2006-02       Impact factor: 3.411

Review 5.  Is race an independent prognostic factor for survival from prostate cancer?

Authors:  M Roach
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

6.  The prevalence of microscopic hematuria in a cohort of women with pelvic organ prolapse.

Authors:  Nirmala Pillalamarri; Dara Shalom; Sharlene Sanidad; Meredith Akerman; Lawrence Lind; Harvey Winkler
Journal:  Int Urogynecol J       Date:  2014-07-01       Impact factor: 2.894

7.  Using urine microscopy and cytology for early detection of bladder cancer in male patients with lower urinary tract symptoms.

Authors:  Eddie S Y Chan; Chi-Fai Ng; See-Ming Hou; Sidney K H Yip
Journal:  Int Urol Nephrol       Date:  2010-11-04       Impact factor: 2.370

Review 8.  The Investigation of Hematuria.

Authors:  Christian Bolenz; Bernd Schröppel; Andreas Eisenhardt; Bernd J Schmitz-Dräger; Marc-Oliver Grimm
Journal:  Dtsch Arztebl Int       Date:  2018-11-30       Impact factor: 5.594

9.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

10.  Bladder tumor in women with microscopic hematuria: an Iranian experience and a review of the literature.

Authors:  Shahin Abbaszadeh; Saeed Taheri; Mohammad Hossein Nourbala
Journal:  Adv Urol       Date:  2009-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.